AR067627A1 - Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion - Google Patents
Enlazador fmoc polimerico hidrolizable. procedimiento de preparacionInfo
- Publication number
- AR067627A1 AR067627A1 ARP080102744A ARP080102744A AR067627A1 AR 067627 A1 AR067627 A1 AR 067627A1 AR P080102744 A ARP080102744 A AR P080102744A AR P080102744 A ARP080102744 A AR P080102744A AR 067627 A1 AR067627 A1 AR 067627A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- radical
- attached
- preparation procedure
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/164—Unsaturated ethers containing six-membered aromatic rings
- C07C43/168—Unsaturated ethers containing six-membered aromatic rings containing six-membered aromatic rings and other rings
Abstract
Conjugados poliméricos basados en Fmoc (9-fluorofenil-metoxicarbonilo). Estos conjugado9s son utiles para extender la circulacion in vivo de drogas con proteínas y péptidos. Reivindicacion 1: Un compuesto de la formula 1 caracterizado porque Z es un grupo saliente y al menos uno de la posicion 1, 2, 3, 4, 5, 6, 7 u 8 está unido al radical Y; Y es un radical que contiene un biopolímero semi-sintético que está unido a una mitad N-succinimidilo; al menos uno de una posicion disponible 1, 2, 3, 4, 5, 6, 7 u 8 está unido opcionalmente al radical X; X es -SO3-R3; R3 está seleccionado independientemente del grupo que consiste en hidrogeno, alquilo C1-8 y alquil C1-8-R4; y R4 es un polímero. Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, caracterizado porque Z es un éster de N-succinimidilo; Y es como en formula (2), polímero es un biopolímero semi-sintético; R1 es en cada caso independientemente un alquilo C1-8; y R2 es seleccionado independientemente del grupo que consiste en -C(O)NR-, -C(O)NR-alquil C1-8-NR-, -NRC(O)- y -NRC(O)-alquil C1-8-NR; R es independientemente hidrogeno o alquilo C1-8. Reivindicacion 14: Un conjugado caracterizado porque comprende el compuesto de cualquiera de las reivindicaciones 1 a 7 y una droga con proteína o péptido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93716907P | 2007-06-26 | 2007-06-26 | |
US12326308P | 2008-04-07 | 2008-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067627A1 true AR067627A1 (es) | 2009-10-21 |
Family
ID=39855055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102744A AR067627A1 (es) | 2007-06-26 | 2008-06-25 | Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion |
Country Status (16)
Country | Link |
---|---|
US (3) | US7700551B2 (es) |
EP (1) | EP2173383B1 (es) |
JP (1) | JP5622569B2 (es) |
KR (1) | KR101654375B1 (es) |
CN (1) | CN101687048B (es) |
AR (1) | AR067627A1 (es) |
AU (1) | AU2008267360B2 (es) |
BR (1) | BRPI0813772A2 (es) |
CA (1) | CA2690554C (es) |
DK (1) | DK2173383T3 (es) |
ES (1) | ES2644453T3 (es) |
HK (1) | HK1142828A1 (es) |
MX (1) | MX2009013682A (es) |
NZ (1) | NZ582669A (es) |
TW (1) | TWI569810B (es) |
WO (1) | WO2009000522A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
US7700551B2 (en) * | 2007-06-26 | 2010-04-20 | Baxter International Inc. | Hydrolysable polymeric FMOC-linker |
NZ623810A (en) | 2009-07-27 | 2015-10-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
ES2597954T3 (es) * | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
US9353172B2 (en) | 2011-07-18 | 2016-05-31 | Arts Biologics A/S | Long acting biologically active luteinizing hormone (LH) compound |
US20150133383A1 (en) | 2012-05-11 | 2015-05-14 | Prorec Bio Ab | Method for diagnosis and treatment of prolactin associated disorders |
CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6680295B1 (en) * | 1994-09-22 | 2004-01-20 | The Administrators Of The Tulane Educational Fund | Method and pharmaceutical composition for prevention and treatment of brain damage |
US6368814B1 (en) * | 2000-12-22 | 2002-04-09 | Roche Diagnostics Corporation | Tricyclic antidepressant derivatives and immunoassay |
CA2843439A1 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
WO2005016973A1 (en) * | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Polysialic acid derivatives |
JP4942014B2 (ja) * | 2004-09-14 | 2012-05-30 | 独立行政法人産業技術総合研究所 | O−結合型糖アミノ酸 |
CN101163506B (zh) * | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
PT2279758E (pt) * | 2005-06-16 | 2015-05-27 | Nektar Therapeutics | Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados |
CA2670618C (en) * | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
US8133865B2 (en) * | 2006-12-27 | 2012-03-13 | Nektar Therapeutics | von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage |
US7700551B2 (en) * | 2007-06-26 | 2010-04-20 | Baxter International Inc. | Hydrolysable polymeric FMOC-linker |
-
2008
- 2008-06-25 US US12/215,218 patent/US7700551B2/en active Active
- 2008-06-25 BR BRPI0813772-2A2A patent/BRPI0813772A2/pt not_active Application Discontinuation
- 2008-06-25 NZ NZ582669A patent/NZ582669A/en unknown
- 2008-06-25 WO PCT/EP2008/005155 patent/WO2009000522A1/en active Application Filing
- 2008-06-25 JP JP2010513749A patent/JP5622569B2/ja active Active
- 2008-06-25 EP EP08759334.9A patent/EP2173383B1/en active Active
- 2008-06-25 ES ES08759334.9T patent/ES2644453T3/es active Active
- 2008-06-25 TW TW097123653A patent/TWI569810B/zh active
- 2008-06-25 KR KR1020107001646A patent/KR101654375B1/ko active IP Right Grant
- 2008-06-25 AR ARP080102744A patent/AR067627A1/es unknown
- 2008-06-25 AU AU2008267360A patent/AU2008267360B2/en active Active
- 2008-06-25 CA CA2690554A patent/CA2690554C/en active Active
- 2008-06-25 DK DK08759334.9T patent/DK2173383T3/en active
- 2008-06-25 CN CN2008800218771A patent/CN101687048B/zh active Active
- 2008-06-25 MX MX2009013682A patent/MX2009013682A/es active IP Right Grant
-
2010
- 2010-01-15 US US12/688,461 patent/US8445544B2/en active Active
- 2010-01-18 US US12/689,096 patent/US20100121028A1/en not_active Abandoned
- 2010-09-30 HK HK10109423.6A patent/HK1142828A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2173383A1 (en) | 2010-04-14 |
MX2009013682A (es) | 2010-08-31 |
EP2173383B1 (en) | 2017-08-09 |
TW200908996A (en) | 2009-03-01 |
JP2010531371A (ja) | 2010-09-24 |
HK1142828A1 (en) | 2010-12-17 |
KR20100039854A (ko) | 2010-04-16 |
TWI569810B (zh) | 2017-02-11 |
US20100121028A1 (en) | 2010-05-13 |
CA2690554A1 (en) | 2008-12-31 |
NZ582669A (en) | 2011-07-29 |
CN101687048A (zh) | 2010-03-31 |
BRPI0813772A2 (pt) | 2014-12-30 |
WO2009000522A1 (en) | 2008-12-31 |
CN101687048B (zh) | 2013-02-27 |
AU2008267360A1 (en) | 2008-12-31 |
JP5622569B2 (ja) | 2014-11-12 |
CA2690554C (en) | 2016-08-16 |
US20090005542A1 (en) | 2009-01-01 |
US7700551B2 (en) | 2010-04-20 |
US20100121034A1 (en) | 2010-05-13 |
AU2008267360B2 (en) | 2013-09-12 |
ES2644453T3 (es) | 2017-11-29 |
US8445544B2 (en) | 2013-05-21 |
DK2173383T3 (en) | 2017-09-25 |
KR101654375B1 (ko) | 2016-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067627A1 (es) | Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion | |
BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
Tian et al. | Effect of stapling architecture on physiochemical properties and cell permeability of stapled α‐helical peptides: a comparative study | |
DE602007011901D1 (de) | Ptiden und zellpenetrierenden peptiden gekoppelt a | |
EP2594581A3 (en) | Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens | |
EP2810661A3 (en) | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids | |
CY1118243T1 (el) | Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα | |
RU2016144055A (ru) | Конъюгаты лекарственного средства с наночастицами | |
ATE533514T1 (de) | Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern | |
AR055179A1 (es) | Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas | |
BRPI0417341A (pt) | fator ix glicopeguilado | |
BR112015004501A2 (pt) | derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo | |
ATE499070T1 (de) | Saugstent | |
CO6210831A2 (es) | Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal | |
AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
MX2019005671A (es) | Sustancias para direccionar diversos organos o tejidos seleccionados. | |
SE0402925D0 (sv) | Novel Compounds | |
KR20170085593A (ko) | 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도 | |
CN117567639A (zh) | 用于细胞内递送装订肽的多肽缀合物 | |
WO2011008863A8 (en) | Stereoisomer peptides and their polymer conjugates for hiv disease | |
ATE555120T1 (de) | Neue antimikrobielle peptide und ihre anwendung | |
DOP2007000121A (es) | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso | |
Dahiya | Total synthesis and biological potential of psammosilenin A | |
US20160009763A1 (en) | Peptide molecular materials | |
CY1119215T1 (el) | Πεπτιδικα αναλογα και συζευγματα αυτων |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |